Market Place
Sourcing Support
FDA Awards Janssen CNPV Voucher for Tec-Dara
15 Dec 2025 //
RAPS
RYBREVANT & LAZCLUZE May Improve Survival in Lung Cancer
07 Sep 2025 //
GLOBENEWSWIRE
Nipocalimab better than FcRn blockers for gMG in 24-week study
25 Jun 2025 //
GLOBENEWSWIRE
Talvey + Tecvayli Combo Shows Deep Responses in Myeloma
15 Jun 2025 //
GLOBENEWSWIRE
IMBRUVICA Combo Shows Edge Over Acalabrutinib in CLL
12 Jun 2025 //
GLOBENEWSWIRE
Darzalex Subcutaneous Regimen Benefits Newly Diagnosed Myeloma
03 Jun 2025 //
GLOBENEWSWIRE
Tremfya approved by European Commission for ulcerative colitis
25 Apr 2025 //
GLOBENEWSWIRE
EU Commission OKs DARZALEX-based Regimen for New Myeloma
09 Apr 2025 //
PR NEWSWIRE
EU Commission OKs RYBREVANT for advanced EGFR-mutated lung cancer
07 Apr 2025 //
GLOBENEWSWIRE
Tremfya® gets CHMP approval for Crohn’s Disease treatment
28 Mar 2025 //
GLOBENEWSWIRE
RYBREVANT plus LAZCLUZE® demonstrates overall survival benefit
26 Mar 2025 //
GLOBENEWSWIRE
CHMP Recommends Subcutaneous Rybrevant for EGFR-mutated NSCLC
03 Feb 2025 //
GLOBENEWSWIRE
Nipocalimab Ph 3 Results For Myasthenia Gravis Published In Lancet
23 Jan 2025 //
GLOBENEWSWIRE
EU Approves Lazcluze + Rybrevant For EGFR-Mutated Lung Cancer
21 Jan 2025 //
GLOBENEWSWIRE
CARVYKTI® Shows Higher MRD Negativity in CARTITUDE-4 Study
10 Dec 2024 //
GLOBENEWSWIRE
DARZALEX SC Regimens Improve MRD Negativity & Survival in Myeloma
09 Dec 2024 //
GLOBENEWSWIRE
Darzalex SC Reduces Risk of Progression in Smouldering Myeloma
08 Dec 2024 //
GLOBENEWSWIRE
TECVAYLI Shows Frontline Potential for Newly Diagnosed Myeloma
08 Dec 2024 //
GLOBENEWSWIRE
CHMP Recommends Rybrevant & Lazcluze® for EGFR-mutant NSCLC
15 Nov 2024 //
GLOBENEWSWIRE
Nipocalimab Demonstrates Disease Control In Myasthenia Gravis Study
15 Oct 2024 //
GLOBENEWSWIRE
TALVEY & DARZALEX Show Durable Responses In Myeloma Patients
27 Sep 2024 //
GLOBENEWSWIRE
CARVYKTI Is First Therapy To Extend Survival For Multiple Myeloma
27 Sep 2024 //
GLOBENEWSWIRE
DARZALEX based quadruplet regimen receives positive CHMP
20 Sep 2024 //
GLOBENEWSWIRE
Dupixent Recommended for EU Approval by the CHMP
20 Sep 2024 //
GLOBENEWSWIRE
TAR-200 Plus Cetrelimab Improves Bladder Cancer Response
16 Sep 2024 //
GLOBENEWSWIRE
RYBREVANT Plus Chemo Shows 49% Response In Colorectal Cancer
14 Sep 2024 //
GLOBENEWSWIRE
RYBREVANT Plus Chemo Shows Positive OS Trend In EGFR-Mutated Lung Cancer
14 Sep 2024 //
GLOBENEWSWIRE
J&J Seeks EU Approval For Nipocalimab In Myasthenia Gravis
12 Sep 2024 //
GLOBENEWSWIRE
RYBREVANT Plus Lazertinib Shows Survival Trend In Lung Cancer
08 Sep 2024 //
GLOBENEWSWIRE
Nipocalimab Phase 3 Trial Shows Sustained Disease Control In Myasthenia Gravis
28 Jun 2024 //
GLOBENEWSWIRE
TAR-210 Shows 90% RFS In High-Risk, 90% Response In Intermediate NMIBC
05 May 2024 //
GLOBENEWSWIRE
TAR-200 Monotherapy >80% Response In High-Risk Bladder Cancer
03 May 2024 //
GLOBENEWSWIRE
